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Summary Somatic mutations in TP53 are seen in many human cancers. In addition, the protein product of
the wild-type TP53 can be sequestered by the protein MDM2 (murine double minute 2). This protein is
commonly overexpressed in human sarcomas and gliomas, usually as a result of gene amplification. In this
study, 43 ovarian carcinomas (OCs) were analysed for aberrations in the TP53 gene by immunohistochemistry
(IHC), loss of heterozygosity (LOH) or mutation analysis. The MDM2 gene and its product was studied by
Southern blotting and IHC. Over 50% of the OCs studied showed mutations in TP53 by either direct
sequencing (19/36. 53%), positive IHC (23,43, 53%) or both, whereas 0/32 had amplification of MDM2 and
only 1/37 tumours had positive IHC using the anti-MDM2 antibody IF-2. The solitary example of positive
IHC in this series was seen in a mixed mullerian tumour with sarcomatous differentiation and was not
accompanied by MDM2 DNA amplification. These results support previous data showing that around 50% of
OCs have mutations in TP53 and in addition, suggest that MDM2 is not amplified in OC, but the presence of
sarcomatous features in mixed muillerian tumours may result in positive immunohistochemistry with IF-2.
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Somatic mutations in TP53 are very common in human
cancer (Hollstein et al., 1991). This 393 amino acid nuclear
phosphoprotein, mapping to 17pl3.1, is active as a transcrip-
tion factor and binds DNA in a sequence-specific manner.
Baker et al. (1989) showed that mutations in the TP53 gene
of two colorectal cancers affected a highly conserved region
of the gene, and was associated with allelic losses of the
wild-type TP53 gene. This suggested that TP53 acts as a
tumour-suppressor gene (TSG). These findings were later
generalised to a number of human cancers (Nigro et al.,
1989), but it was emphasised in this paper that mutation of
TP53 was not always associated with LOH on 17p.
Previous studies of TP53 in sporadic OC have shown that
mutations are present in up to 80% of OCs (Marks et al.,
1991; Mazars et al., 1991; Okamoto et al., 1991; Kohler et
al., 1993a,b; Kupryjanczyk et al., 1993; Milner et al., 1993;
Teneriello et al., 1993). Taken together, these studies demon-
strate that
(1) Mutation of TP53 is usually accompanied by overexpres-
sion of TP53 protein as detected by most of the anti-p53
monoclonal antibodies and vice versa, but there are a
number oftumours where this relationship does not hold.
(2) Mutation of TP53 is commonly associated with LOH of
the wild-type allele, but often there is LOH over the
whole of chromosome 17.
(3) TP53 mutation occurs before metastatic spread, and is
less common in early-stage than late-stage disease.
(4) There is no strong evidence that any particular type of
mutation (transition, tranverserion, mutation hotspot) is
overrepresented in OC.
(5) Mutations in TP53 and RASK are not seen in the same
tumour.
(6) There is no clear prognostic information to be gathered
from the presence of a TP53 mutation in any given OC.
An amplified murine gene, mdm2 (murine double minute 2)
was cloned from a transformed mouse 3T3 cell line (Cahilly-
Synder et al., 1987). The human homologue, MDM2, mapp-
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ing to 12q13-14, is amplified in a number of human cancers,
particularly sarcomas and gliomas (Oliner et al., 1992; Leach
et al., 1993; Reifenberger et al., 1993). The product of this
gene complexes with wild-type TP53 and can abolish its
trans-activating properties (Momand et al., 1992), probably
by masking the activation domains of TP53 (Oliner et al.,
1993). Therefore, in a given tumour, one might expect to see
mutations of TP53, with or without LOH on 17p, or
amplification of MDM2, but not both. This has been shown
to be the case for soft tissue sarcomas and gliomas (Leach et
al., 1993; Reifenberger et al., 1993).
As the relationship between TP53 and MDM2 has not
been analysed in OC, in this study of 43 OCs we set out to
search for mutations in TP53, as identified by single-strand
conformation polymorphism (SSCP) analysis of exons 5-8,
direct sequencing and IHC, and amplification and overex-
pression of MDM2 in the same OCs.
Materials and methods
Histopathology, DNA extraction and Southern hybridisation
Histopathological categorisation, tumour grading, DNA ext-
raction and Southern hybridisation were carried out as des-
cribed in our previous publication (Foulkes et al., 1993a).
Table I shows the histopathological subtype of each tumour
studied. Cryostat sections were taken from each tumour to
ensure that stromal 'contamination' was kept to a minimum.
DNA was then extracted from the tumours and lymphocytes
as described previously.
TP53 LOHstudies
There were carried out as described in Foulkes et al. (1993b).
LOH was studied using a bglII restriction fragment length
polymorphism (RFLP) within the TP53 gene (De La Calle et
al., 1990) and using the highly informative dinucleotide
repeat that lies near TP53 (Jones and Nakamura, 1992).
Some of this work has been previously reported (Foulkes et
al. 1993b) but here we present an extended analysis.A p53 and MDM2 in ovarian cancer
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Table I Histopathological details,
Histopathological
type
SPAC
SPAC
SPAC
SPAC
SPAC
SPAC
AC/UD
EC
AC/UD
SPAC
SPAC
SPAC
MAC
AC/UD
SPAC
SPAC
SPAC
SPAC
SPAC
AC/UD
AC/UD
EC
EC
AC/UD
SPAC
MMT
MAC
SPAC
SPAC
SPAC
SPAC
MAC
EC
SPAC
MMT
MAC
SPAC
SPAC
MMT
SPAC
EC
SPAC
SPAC
Grade8
3
2-3
2
3
3
3
3
2
3
3
2-3
2
2
3
2
3
3
3
3
2
3
3
3
3
2-3
3
1
3
3
3
2-3
1
2
3
3
1
2
3
2
2-3
2
3
3
Stage
NA
III
NA
NA
IlIc
NA
III
NA
II
IlIc
III
NA
IV
NA
III
III
III
II
II
IV
NA
III
III
NA
III
III
NA
NA
III
III
NA
III
III
III
III
III
IV
IV
II
IV
Ic
IV
III
TPS3 mutation. LOH on 17p and p53 and MDM2 immunohistochemistry
TP53
LOH
+
+
+
+d
+
ND
+
NI
ND
ND
ND
+
_ d
+
+
+ d
+
NI
+
NI
NI
TPS3b
IHC
+FC
+
+
+ P
+
+
+
+
TP53 mutationc
codon, base change
173, GTG ATG
175, CGC+CAC
176-182, 19 bp deletion
179, CAT-+CGT
179, CAT->CGT
220, TAT+TGT
220, TAT-TGT
220, TAT+TGT
220, TAT-TGT
220, TAT+TGT
236, TAC+TGC
248, CGG+TGG
272, GTG ATGe
273, CGT+TGT
273, CGT+TGT
273, CGT+TGP
281, GAC + GGC
282, CGG +TGG
282, CGG+TGG
Mutation, but not identified
ND
ND
ND
ND
ND
ND
Mutation
type
T
CpG
T
T
T
T
T
T
T
T
CpG
T
CpG
CpG
CpG
T
CpG
CpG
Amino acid
change
Val+Met
Arg- His
frameshift
His+Arg
His- Arg
Tyr Cys
Tyr Cys
Tyr Cys
Tyr Cys
Tyr Cys
Tyr Cys
Arg-+Trp
Val+Met
Arg+Cys
Arg+Cys
Arg+Cys
Asp Gly
Arg+Trp
Arg-*Gly
MDM2
IHC
ND
ND
ND
ND
ND
ND +D
'For details of grading system, see Foulkes et al. (1993a). bp53 Immunohistochemistry was performed with antibodies CMI, PAb 421 and
D07 (anti-p53). cMutation type: CpG indicates a GC-+AT transition at CpG dinucleotide; T, transition. dIn these cases, the two TPS3 probes
used were not informative. However, a probe nearby gave the result shown. These cases gave all the same LOH result (+ or -) over the whole
chromosome making it likely that, ifinformative, the TP53 result would have been as indicated. eVery faint band, probably affecting 5% DNA.
Percentage tumour/stroma in these two cases is; tumour 67, 40/60%; tumour 75, 50/50%. See text for further discussion.
AC/UD, adenocarcinoma, undifferentiated lineage; SPAC, serous papillary (cyst) adenocarcinoma (including serous carcinoma, papillary
carcinoma and serous adenocarcinoma); MAC, mucinous adenocarcinoma; EC, endometrioid carcinoma; MMT, mixed mullerian tumour. NA,
not available; ND, not done; NI, not informative; FCP, few cells positive.
TP53 SSCP and sequencing analysis
Polymerase chain reactions (PCRs) using the TP53 primers
were carried out as described in Milner et al. (1993) with
some modifications. After standard treatment, the samples
were placed on wet ice before loading onto 6% non-
denaturing polyacrylamide gels (59:1 acrylamide:bis-
acrylamide) containing 5% glycerol and 0.5 x TBE. Elect-
rophoresis was carried out overnight at between 150 and
350 V. After electrophoresis, the gels were transferred to
Whatman 3MM paper, vacuum dried and exposed to Kodak
X-AR film overnight at room temperature. If band shifts
were not seen under these conditions, the reaction products
were run again (in 1 x TBE) in a gel containing 10%
glycerol. Any tumours with SSCP band shifts were sequenced
using a modification (Powis et al., 1992) of standard method.
The sequencing gels were fixed in 10% methanol, 10% acetic
acid, vacuum dried and exposed to Kodak X-AR film over-
night at room temperature.
Immunohistochemistry: TP53 and MDM2
This was carried out on 4 ltm sections from formalin-fixed
paraffin-embedded tissue (antibodies CM1 and D07), as well
as on 6iLm cryostat sections (antibodies PAb 421 and IF-2).
The sections were immunostained with these polyclonal and
monoclonal antibodies using a standard avidin-biotin per-
oxidase technique as described previously (Pignatelli et al.,
1992). All primary antibodies were incubated at 25°C for 1 h
at appropriate dilutions: neat (HMFG2 and o6-integrin-
psotive controls), 1:10 (MDM2), 1:100 to 1:200 (DO7, 421)
and 1:1000 (CM1). In some cases, CM1 was incubated at a
dilution of 1 in 2000 at 4°C overnight. All the stained sec-
tions were revieved by GWHS. Tumours were assessed as
positive when there was unequivocal reproducible nuclear
staining of at least 5-10% of the neoplastic cells, assessed as
weak, moderate or strong. In practice, in the positive
tumours, a greater percentage of positive cells were present.
Cytoplasmic staining was ignored as false-positive reactions
are known to occur (e.g. with CM1). Positive controls were
used in all cases, and immunostaining was repeated if there
was any uncertainty.
MDM2 genomic amplification analysis
MDM2 gene amplification was assessed by Southern blotting
with a 1.6 kb cDNA probe, pHDM (Chen et al., 1993). The
Tumour
number
11
32
85
17
80
10
24
42
64
83
29
20
75
7
61
67
88
37
48
47
9
35
40
63
71
84
13
18
25
27
28
30
31
41
50
51
53
72
73
77
78
81
91intensity of the autoradiographic signals obtained were com-
pared with DNA loading by comparison with previous hyb-
ridisation signals performed on the same blots. Additionally,
all blots were hybridised with a probe for the RET proto-
oncogene (Mulligan et al., 1993), which is a single-copy gene
on chromosome 10q1 1.2.
Results
Mutation, immunohistochemistry and loss ofheterozygosityfor
TP53
We analysed our series of tumours for aberrations in TP53
by SSCP followed by direct sequencing, IHC with three
anti-p53 antibodies and by LOH using a highly polymorphic
dinucleotide repeat marker. Using this combined approach
we have shown that 19/36 OCs had mutations in TP53 by
DNA sequence analysis, performed as a result of an aber-
rantly migrating PCR fragment seen on SSCP (Table I).
Eighteen of these mutations were missense mutations and
one was a deletion (tumour 47 showed a very clear band shift
with SSCP analysis, but despite many attempts, this tumour
could not be sequenced and therefore this tumour has been
included as 'mutation, but not identified'). The 18 base sub-
stitutions seen in this series of 35 OCs were all transitions,
with 50% being at GC->AT, (39% at CpG sites and 11% at
other sites) and 50% were AT->GC transitions. Five out of
these 9 AT-*GC transitions were at codon 220,
TAT-*TGT, changing the amino acid sequence from
tyrosine to cysteine. Thus no transversions or complex subs-
titutions were seen. The deletion (tumour 85) would result in
a frame-shift and therefore would be likely to produce a
truncated protein. This case was positive for p53 IHC.
Twenty-three of 43 OCs (53%) were positive by IHC with
the anti-p53 antibodies PAb 421, D07 or CM1. All three
antibodies were used where tissue was available, and no
discordant results in terms of positive vs negative immunos-
taining were obtained using these three antibodies. The cor-
relation between mutation in TP53 and positive IHC was
highly significant (Fisher's exact test, P<0.001) (Table II).
However, the common mutation in our series is codon 220,
TAT>TGT, Tyr>Cys and the IHC results were not com-
pletely concordant for these five tumours. The five tumours
were no. 10, a serous papillary adenocarcinoma, (SPAC); no.
24, an undifferentiated adenocarcinoma, (AC/UD); no. 42,
an endometrioid carcinoma; no. 64, an AC/UD; and no. 83,
a SPAC. Tumour 10 showed clear LOH at TP53 and a
mutation in exon 6, as did the other four cases (Table I).
Despite the differing histology, all except tumour 10 were
positive for IHC with the anti-p53 antibodies used. It is
possible that another mutation has occurred in this tumour
outside exons 5-8 which prevents protein from being pro-
duced, resulting in negative IHC. Alternatively, the protein
may have become destabilised in the period between tumour
removal and snap freezing, although from our positive results
with this tumour using other antibodies (not shown) this
seems unlikely. There were two other tumours that had TP53
Table II Comparison between mutations in TPS3 and positive
immunohistochemistry
Positive IHC Negative IHC
Mutation in TPS3 17 3
No mutation in TP53 0 17
p53 and MDM2 inovaran cancer
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mutations but negative IHC. These were tumours 29 and 32,
both serous papillary adenocarcinomas with mutations in
TPS3 at codons 236 and 175 respectively (Tables I and II).
A PCR-based analysis of LOH at the TP53 locus showed
that 26/35 (74%) of the informative tumours that were
studied at this, or in four cases an adjacent locus, demon-
strated LOH. The correlation between TP53 mutation and
LOH is shown in Table III. It can be seen that while there is
a good correlation between mutations in TPS3 and LOH at
this locus (Fisher's exact test, P = 0.059), LOH at TP53
without mutations in this gene was not uncommon. This is
probably because other, as yet uncloned, TSGs on
a
B
T
A > G
C
an- -.
Coden 7
C
Fisher's exact test, P<0.001.
Figure 1 TP53 loss of heterozygosity, sequencing and
immunohistochemistry results for tumour 80. (a) Microsatellite
analysis of normal (N) and tumour (T) genomic DNA at the
TP53 locus showing complete loss of the smaller allele in the
tumour. (b) DNA sequence of a portion of exon 5 of TP53
showing an A to G transition at codon 179. (c) Positive p53
immunostaining using antibody D07.
Table III Comparison between mutations in TP53 and LOH
LOH at TP53 No LOH at TP53
Mutations in TP53 17 3
No mutations in TP53 7 6
Fisher's exact test, P = 0.059.p53 and MDM2 in ovarian cancer
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chromosome 17 are 'driving' the LOH. Similarly, there are
three cases with mutations but no LOH. As these are all late
stage, moderate-to-high-grade tumours, it seems unlikely that
in these cases TP53 mutation is an early event (with LOH to
follow). Examples of LOH at TP53, mutation in TP53 and
positive IHC with monoclonal antibody D07 are shown in
Figure 1 (tumour 80). Interestingly, this tumour shows com-
plete LOH but the wild-type genotype is clearly visible on the
sequencing gel, suggesting that LOH with reduplication or
recombination preceded mutation in TP53.
MDM2 amplifications and over-expression
Southern blots of tumour and normal DNA were probed
with an MDM2 cDNA, pHDM. The intensity of the hyb-
ridising bands was compared with the DNA loaded onto the
gel by assessment of both ethidium bromide staining and the
hybridisation signals obtained with a probe for the RET
proto-oncogene, an example of which is shown in Figure 2.
This probe detects a single copy gene on chromosome
1Oql 1.2, a region that is not noted for its deletion or
amplification in ovarian cancers. Additionally these filters
have been hybridised with a variety of polymorphic DNA
probes in previous LOH studies and these assisted in verify-
ing the DNA loading. MDM2 amplification, if present, is
generally in the order of 5-8 fold which is easily detectable
on Southern blots (Reifenberger et al., 1993). However, we
found no discernable variation in MDM2 hybridisation sig-
nals among the 32 tumours studied. Interestingly, no DNA
a
amplification was evident in tumour 73 which was positive
for MDM2 by IHC (see below).
Thirty-seven tumours were examined for MDM2 protein
overexpression by IHC using the antibody IF-2. Only one
tumour, 73, showed positive MDM2 IHC (Figure 3). This
tumour was negative for p53 IHC and TP53 mutation. Inter-
estingly, this was a mixed mullerian tumour with histological
features similar to sarcomas, a tumour type where MDM2
amplification and over-expression is frequently observed.
Discussion
Here we present the first account of a combined approach to
the analysis of TP53 and MDM2 aberrations in sporadic OC.
We have demonstrated that
a
9 .1
b
b
c
c
Figure 2 Southern blot (BamHI-digested DNA) analysis of the
MDM2 gene in some representative tumours (a) showing no
amplification. There were no significant differences in DNA
loading as demonstrated by the signals obtained with a probe for
the RET proto-oncogene (b) or by comparison with the ethidium
bromide stained gel from which the Southern blot was derived
(c).
Figure 3 MDM2 immunohistochemistry using antibody IF-2. (a)
Positive MDM2 immunostaining with tumour 73. (b) Positive
MDM2 immunostaining in a mammary carcinoma. (c) Absence
of staining on an endometrioid carcinoma.p53 and MDM2 in ovarian cancer
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(1) Twenty-six of 35 (74%) informative OCs have LOH on
chromosome 17p at the TP53 locus.
(2) Nineteen of 36 (53%) OCs have mutations in codons 5-8
of TP53.
(3) Twenty-three of 43 (53%) OCs have positive IHC using
anti-p53 antibodies.
(4) None of 32 OCs had MDM2 amplification by Southern
blotting using the MDM2 cDNA.
(5) One of 37 tumours (2.7%) had positive IHC which did
not accompany DNA amplification.
The results we have obtained at the TP53 locus are in
keeping with previous studies of OC showing that approx-
imately 50% of all OCs have mutations in TP53 exons 5-8.
The spectrum of mutations we observed differ slightly from
the experience of other groups, in that all the missense
mutations we found were transitions, whereas in a review of
all OC cases reported 93/128 mutations were transitions
(73%) and 35/128 (27%) were transversions (Kohler et al.,
1993b). The smaller numbers in our series may account for
the differences seen. This study supports the conjecture that
environmental toxins are unlikely to be responsible for TP53
mutations in OC (Kohler et al., 1993b).
It has been suggested that mutations in TP53 and amplifi-
cation of MDM2 in the same tumour are biologically redun-
dant, in that both alterations have the same effect: loss of
p53 function. Thus, in our series of OCs we studied MDM2
amplification and over-expression in order to determine
whether MDM2 was aberrant in OC and if so, whether
amplification and/or overexpression was limited to those
tumours without TP53 alterations. Of 43 OCs available, 32
were studied by Southern blotting using an MDM2 cDNA
and 37 by IHC using the antibody IF-2. No tumours showed
amplification, and only one tumour, a mixed miillerian
tumour, demonstrated overexpression. Therefore in OC,
regulation of TP53 does not appear to be mediated by
MDM2 overexpression.
The tumour showing positive IHC with IF-2, tumour 73, is
negative for IHC with anti-p53 antibodies and does not have
a mutation in exons 5-8 of TP53. This mixed miillerian
tumour is, to our knowledge, the only ovarian tumour to be
described that demonstrates an overexpression of MDM2
protein. The fact that the tumour displays sarcomatous
features is intriguing, as it is soft-tissue sarcoma (Leach et al.,
1993; Cordon-Cardo et al., 1994; Florenes et al., 1994a;
Patterson et al., 1994), and to a lesser extent gliomas
(Reifenberger et al., 1993) and osteosarcomas (Ladanyi et al.,
1993; Florenes et al., 1994a), that most commonly show
amplification and/or overexpression of MDM2. There may
be particular features of the differentiation of mesenchymal
tissue that favour the accumulation of quantitatively abnor-
mal MDM2 protein.
The presence of overexpressed MDM2 in the absence of
amplification has been reported in two series of sarcomas
(Cordon-Cardo et al., 1994; Florenes et al., 1994a) and,
perhaps surprisingly, in 25 out of 87 bladder cancers in one
series (Lianes et al., 1994). In this latter series, only one
tumour had DNA amplification and overexpression, which
suggests that MDM2 overexpression in bladder cancer may
have different biological implications from that seen in sar-
comas, especially as the same group found that overexpres-
sion was significantly associated with low-grade, early-stage
tumours. The significance of overexpression of MDM2 with-
out amplification is uncertain: it has been suggested that in
this context MDM2 expression (to levels detectable by IHC)
may be a response to wild-type TP53 (Meltzer, 1994). Our
findings with tumour 73 would support this view. However,
we did not see any MDM2 overexpression in the other 16
OCs in our series that lacked mutations in TP53 exons 5-8.
The spectrum of tumours that show MDM2 amplification
and/or overexpression has been studied by several groups. In
general, it appears that MDM2 amplification and/or overexp-
ression is present in up to one-third of all soft-tissue sar-
comas and about 10% of glioma and metastatic osteosar-
comas. In contrast, MDM2 amplification and/or overexpres-
sion is very uncommon or absent in colon carcinoma (Oliner
et al., 1992), Ewing's sarcoma (Kovar et al., 1993), gastric
carcinoma (Oliner et al., 1992), hepatoblastoma (Waber et
al., 1993), leukaemia (Ridge et al., 1994), malignant
melanoma (Florenes et al., 1994b), myelodysplastic synd-
romes (Preudhomme et al., 1993), neuroblastoma (Waber et
al., 1993), oesophageal carcinoma (Esteve et al., 1993),
ovarian carcinoma (this report), upper aerodigestive tract
squamous carcinoma (Waber et al., 1993), uterine cervix
carcinoma (Kessis et al., 1993) or Wilms' tumour (Waber et
al., 1993). The question of MDM2 involvement in bladder
cancer is unresolved as, though amplification of MDM2 was
rare in two independent studies (2/50, Habuchi et al., 1994;
1/87, Lianes et al., 1994), the latter group found that overex-
pression without amplification was common (25/87).
Our results confirm the importance of TP53 in OC.
Indeed, aberrant TP53 expression is one of the commonest
genetic defects seen in human cancers (Hollstein et al., 1991).
The abnormal expression commonly results from mutations
in the coding region of TP53. However, the finding that
MDM2, a protein that binds p53, was amplified in sarcomas
that did not show mutations in TP53 (Oliner et al., 1992)
suggested that this might be an alternative way of abrogating
p53 function. The importance of MDM2 in soft-tissue sar-
comas is clear, but taking all-the published data together it
appears that in many human cancers p53 is not commonly
inactivated by sequestration through MDM2 amplification. It
may be that MDM2 has a particular role in mesenchymal
tumours, but MDM2 amplification in the common adult
cancers (where TP53 mutations are frequent) is uncommon.
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